|Bid||14.54 x N/A|
|Ask||14.98 x N/A|
|Day's Range||14.46 - 15.02|
|52 Week Range||9.49 - 20.16|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health market, will gather data for the upcoming launch.
Lipidor AB (publ) (Nasdaq First North: LIPI) today provides an update on the planned Phase III study of the company's drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for commencement of the Phase III study. As Lipidor has previously announced, the main purpose of the study is to compare the therapeutic efficacy of AKP02 with existing medicines for mild to moderate psoriasis. Results from the study are expected in the first half of 2022.
Lipidor AB (Nasdaq First North:LIPI) today announced that the Company has signed an exclusive licensing agreement with Cannassure Therapeutics Ltd. (TASE:CSURE), an Israeli company specializing in the development and manufacture of innovative medicinal cannabis products. Under the agreement, Cannassure has the exclusive right to use Lipidor's proprietary drug delivery technology AKVANO® in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions. Lipidor receives a royalty of 15-17.5% on future product sales. When a predetermined accumulated sales volume is achieved, Lipidor will receive an additional milestone payment in the form of 1% of the share capital value of Cannassure, up to a maximum of EUR 350,000. Lipidor's projection is that this milestone compensation will be paid within a two-year period.